Dyne Therapeutics BLA for DMD drug gets Priority Review

Rhea-AI Filing Summary

Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted for review its biologics license application for zeleciment rostudirsen (z‑rostudirsen, also known as DYNE‑251) to treat individuals with Duchenne muscular dystrophy amenable to exon 51 skipping. The FDA granted Priority Review and set a Prescription Drug User Fee Act target action date of January 21, 2027.

The company stated it continues to expect a potential U.S. launch of z‑rostudirsen in the first quarter of 2027, assuming approval is received on this anticipated timeline. Dyne also emphasized that these expectations are forward‑looking and subject to substantial risks and uncertainties, including clinical, regulatory and financing factors described in its SEC reports.

Positive

• FDA acceptance and Priority Review of Dyne’s biologics license application for z‑rostudirsen (DYNE‑251) in Duchenne muscular dystrophy, with a PDUFA target action date of January 21, 2027, supporting a company expectation of a potential U.S. launch in the first quarter of 2027, assuming approval.

Negative

• None.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

PDUFA target action date: January 21, 2027 Expected U.S. launch timing: first quarter of 2027 Exon target: exon 51

3 metrics

PDUFA target action date January 21, 2027 FDA target action date for the Priority Review of the BLA for z-rostudirsen

Expected U.S. launch timing first quarter of 2027 Company’s expectation for a potential U.S. launch of z-rostudirsen, assuming FDA approval on the anticipated timeline

Exon target exon 51 Z-rostudirsen is intended for DMD patients amenable to exon 51 skipping

Key Terms

biologics license application, Priority Review, Prescription Drug User Fee Act, Duchenne muscular dystrophy, +1 more

5 terms

biologics license application regulatory

"FDA has accepted for review its biologics license application for zeleciment rostudirsen"

A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

Priority Review regulatory

"The FDA has granted the BLA Priority Review and assigned a PDUFA target date"

Priority review is a regulatory fast-track that shortens the time an agency spends evaluating a drug, vaccine or medical device application so a decision comes sooner than normal. For investors, it matters because a faster review is like an express lane to market: it can speed revenue potential and reduce regulatory uncertainty, but it does not guarantee approval and still requires the product to meet safety and effectiveness standards.

Prescription Drug User Fee Act regulatory

"assigned a Prescription Drug User Fee Act target action date of January 21, 2027"

A federal program that lets drug makers pay fees to the U.S. regulator to fund and speed up the review of new medicines and label changes. Investors care because it affects how quickly a drug can move from testing to market and how predictable approval timelines and regulatory interactions are — like buying a faster lane at a busy checkpoint that can reduce uncertainty about a product’s commercial timing.

Duchenne muscular dystrophy medical

"for the treatment of individuals with Duchenne muscular dystrophy amenable to exon 51 skipping"

A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.

forward-looking statements regulatory

"contains forward-looking statements that involve substantial risks and uncertainties"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dyne Therapeutics (DYN) report about z-rostudirsen (DYNE-251)?

Dyne Therapeutics reported that the FDA has accepted for review its biologics license application for z‑rostudirsen (DYNE‑251) to treat Duchenne muscular dystrophy amenable to exon 51 skipping and has granted the application Priority Review, establishing an expedited regulatory timeline.

What is the FDA PDUFA target action date for Dyne Therapeutics (DYN)?

The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 21, 2027 for Dyne Therapeutics’ biologics license application for z‑rostudirsen, defining when the agency currently expects to complete its Priority Review of the submission.

When could Dyne Therapeutics (DYN) potentially launch z-rostudirsen in the U.S.?

Dyne Therapeutics stated it continues to expect a potential U.S. launch in the first quarter of 2027 for z‑rostudirsen, assuming the FDA approves the biologics license application on the anticipated Priority Review timeline tied to the January 21, 2027 PDUFA date.

For which patients is Dyne Therapeutics (DYN) seeking approval of z-rostudirsen?

The biologics license application seeks approval of z‑rostudirsen for the treatment of individuals with Duchenne muscular dystrophy who are amenable to exon 51 skipping, targeting a specific genetic subset of DMD patients based on their mutation profile.

What risks did Dyne Therapeutics (DYN) highlight regarding its forward-looking statements?

Dyne highlighted that its expectations are forward-looking statements subject to substantial risks, including uncertainties in preclinical and clinical development, regulatory interpretation and approval, adequacy of cash resources, and other factors discussed in its most recent Form 10‑Q and subsequent SEC filings.

How does the FDA Priority Review affect Dyne Therapeutics (DYN) and z-rostudirsen?

The FDA’s Priority Review designation for z‑rostudirsen shortens the targeted review timeline and is accompanied by a PDUFA target action date of January 21, 2027, framing expectations for when the agency may act on the biologics license application.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/20/2026 - 07:35 AM EDT Learn about SEC filing dates

0001818794false00018187942026-07-202026-07-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 20, 2026

Dyne Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-39509	36-4883909
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
1560 Trapelo Road Waltham, Massachusetts		02451
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 786-8230

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value per share		DYN		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On July 20, 2026, Dyne Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review its biologics license application (“BLA”) for zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for the treatment of individuals with Duchenne muscular dystrophy (“DMD”) amenable to exon 51 skipping. The FDA has granted the BLA Priority Review and assigned a Prescription Drug User Fee Act target action date of January 21, 2027. The Company continues to expect a potential U.S. launch of z-rostudirsen in the first quarter of 2027, assuming approval is received on the anticipated timeline.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including statements regarding the Company’s strategy, future operations, prospects and plans, objectives of management, the potential of the FORCETM platform, the clinical and therapeutic potential of z-rostudirsen, the potential of z-rostudirsen to advance the treatment paradigm in Duchenne muscular dystrophy, expectations regarding the timing and outcome of interactions with regulatory authorities and the timing of regulatory authority action, and expectations regarding the timing of commercialization of z-rostudirsen, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; uncertainties as to the FDA’s and other regulatory authorities’ interpretation of the data from the Company’s clinical trials and the regulatory approval process; whether the Company’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s most recent Form 10-Q and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company’s views as of the date of this Current Report. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		DYNE THERAPEUTICS, INC.
Date: July 20, 2026		By:		/s/ John G. Cox
				Name:		John G. Cox
				Title:		President and Chief Executive Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 30.0 KB